NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 207 filers reported holding NEKTAR THERAPEUTICS in Q1 2017. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $633,000 | +6.0% | 10,381 | -15.0% | 0.50% | +205.5% |
| Q2 2018 | $597,000 | -86.2% | 12,216 | -70.0% | 0.16% | -72.8% |
| Q1 2018 | $4,325,000 | +145.2% | 40,700 | +37.8% | 0.60% | +184.0% |
| Q4 2017 | $1,764,000 | +490.0% | 29,540 | +93.1% | 0.21% | +488.9% |
| Q2 2017 | $299,000 | -57.5% | 15,300 | -49.0% | 0.04% | -58.6% |
| Q1 2017 | $704,000 | +200.9% | 30,000 | +57.1% | 0.09% | +107.1% |
| Q4 2016 | $234,000 | – | 19,100 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |